Endocrine Resistance Therapy in Early-Stage Breast Cancer

August 21, 2014
Lori Goldstein, MD

Lori Goldstein, MD, director, The Naomi and Phil Lippincott Breast Evaluation Center, deputy associate director, Clinical Research, Fox Chase Cancer Center, discusses the possibility of using endocrine resistance therapy to treat patients with early stage breast cancer.

Lori Goldstein, MD, director, The Naomi and Phil Lippincott Breast Evaluation Center, deputy associate director, Clinical Research, Fox Chase Cancer Center, discusses the possibility of using endocrine resistance therapy to treat patients with early stage breast cancer.

Clinical Pearls:

  • Clinical trials are examining novel endocrine resistance therapies in the metastatic setting as well as the adjuvant and neoadjuvant setting.